| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/28/2014 | US8637083 Stable formulations for lyophilizing therapeutic particles |
| 01/28/2014 | US8637080 Rupturing controlled release device comprising a subcoat |
| 01/28/2014 | US8637073 Treatment of dependence withdrawal |
| 01/28/2014 | US8637068 Hypotensive prostamide-containing biodegradable intraocular implants and related methods |
| 01/28/2014 | US8637063 Hydrolyzed hydrogels |
| 01/28/2014 | US8637060 Spot-on pesticide composition |
| 01/28/2014 | US8637058 Compositions based on cupric salts, cupric salts and their use for controlling phytopathogens |
| 01/28/2014 | US8637056 Mixture of fatty acid esters of natural origin and its use in cosmetic preparations based on olive oil derivatives |
| 01/28/2014 | US8637054 Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
| 01/28/2014 | US8637049 Attenuated live vaccines for aquatic animals |
| 01/28/2014 | US8636997 Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist |
| 01/28/2014 | US8636996 Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate |
| 01/28/2014 | US8636994 Polymer-based compositions and conjugates of antimicrobial agents |
| 01/28/2014 | US8636988 Composition for treatment of sunburned skin |
| 01/28/2014 | CA2779630C Combination of azelastine and steroids |
| 01/28/2014 | CA2773555C Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof |
| 01/28/2014 | CA2745715C Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof |
| 01/28/2014 | CA2738814C Hiv integrase inhibitors |
| 01/28/2014 | CA2736019C Methods and compositions for treating ectoparasite infestation |
| 01/28/2014 | CA2735229C Combination therapy for tuberculosis |
| 01/28/2014 | CA2723458C Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 01/28/2014 | CA2721927C Auris formulations for treating otic diseases and conditions |
| 01/28/2014 | CA2716320C Selective androgen receptor modulators |
| 01/28/2014 | CA2686468C Polyhydroxylated aromatic compounds for the treatment of amyloidosis |
| 01/28/2014 | CA2685266C Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| 01/28/2014 | CA2683958C Topical fungicidal agents for treating nail disorders |
| 01/28/2014 | CA2652280C Polymers for functional particles |
| 01/28/2014 | CA2651086C Use of type v phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine |
| 01/28/2014 | CA2647592C Inhibitors of polo-like kinases |
| 01/28/2014 | CA2644910C Indazole compounds |
| 01/28/2014 | CA2631741C Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| 01/28/2014 | CA2623450C Methods and compositions for improving cognitive function |
| 01/28/2014 | CA2621040C 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| 01/28/2014 | CA2618974C Nanoemulsion compositions having anti-inflammatory activity |
| 01/28/2014 | CA2617213C Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| 01/28/2014 | CA2616877C Systems and methods for manufacturing liposomes |
| 01/28/2014 | CA2614193C Zofenopril calcium in polymorph form c |
| 01/28/2014 | CA2611011C Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
| 01/28/2014 | CA2609659C Azanaphthalenes, compositions and methods for treating retinal disease |
| 01/28/2014 | CA2608929C Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase |
| 01/28/2014 | CA2598503C New ophthalmologic compositions and their method of use |
| 01/28/2014 | CA2592030C Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| 01/28/2014 | CA2580749C Quinolone analogs |
| 01/28/2014 | CA2576269C Combinations for the treatment of diseases involving cell proliferation |
| 01/28/2014 | CA2568008C Process for preparing acyclic hcv protease inhibitors |
| 01/28/2014 | CA2565347C Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies |
| 01/28/2014 | CA2556870C Dopamine-agonist combination therapy for improving sleep quality |
| 01/28/2014 | CA2554030C Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders |
| 01/28/2014 | CA2535265C Compositions and methods for the treatment of disease associated with trp-p8 expression |
| 01/28/2014 | CA2524036C Treatment of neurodegenerative conditions |
| 01/28/2014 | CA2508170C Pyrazine-based tubulin inhibitors |
| 01/28/2014 | CA2499254C Local vascular delivery of 2-methoxyestradiol in combination with rapamycin to prevent restenosis following vascular injury |
| 01/28/2014 | CA2484318C Warming and nonirritating lubricant antifungal gel compositions |
| 01/28/2014 | CA2464867C Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
| 01/28/2014 | CA2459168C Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol |
| 01/28/2014 | CA2399063C A method for maintaining or improving the synthesis of mucins |
| 01/24/2014 | CA2817141A1 Method and treatment for the reduction of atherosclerosis |
| 01/23/2014 | WO2014015347A1 Compositions and methods for preventing infectious diseases in females |
| 01/23/2014 | WO2014015341A2 Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation |
| 01/23/2014 | WO2014015291A1 FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX |
| 01/23/2014 | WO2014015280A1 Combination therapy of inhibitors for igf1 r and pi3k |
| 01/23/2014 | WO2014015276A1 α-AND γ-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| 01/23/2014 | WO2014015247A1 Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| 01/23/2014 | WO2014015246A1 Difluorolactam compositions for ep4-mediated osteo related diseases and conditions |
| 01/23/2014 | WO2014015244A1 Compositions comprising crosslinked cation-binding polymers |
| 01/23/2014 | WO2014015240A1 Compositions comprising crosslinked cation-binding polymers |
| 01/23/2014 | WO2014015235A2 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof |
| 01/23/2014 | WO2014015183A1 Ophthalmic formulation and method for ameliorating presbyopia |
| 01/23/2014 | WO2014015175A1 Compositions and methods for modulating brd4 bioactivity |
| 01/23/2014 | WO2014015157A2 Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| 01/23/2014 | WO2014015153A2 Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 |
| 01/23/2014 | WO2014015150A2 Poloxamers for the improvement of respiratory function |
| 01/23/2014 | WO2014015136A2 Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid |
| 01/23/2014 | WO2014015125A1 Fused aminodihydrothiazine derivative salts and uses thereof |
| 01/23/2014 | WO2014015107A1 Dosing regimen for janus kinase (jak) inhibitors |
| 01/23/2014 | WO2014015105A1 Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
| 01/23/2014 | WO2014015088A1 Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| 01/23/2014 | WO2014015067A2 Composition comprising scirpusin a and scirpusin b anti-obesity potential thereof |
| 01/23/2014 | WO2014015054A1 Beta amino acid derivatives as integrin antagonists |
| 01/23/2014 | WO2014015047A1 Compositions and methods to treat neurodegenerative diseases |
| 01/23/2014 | WO2014015024A2 Non-surgical method of treatment for cataract |
| 01/23/2014 | WO2014014960A1 Treating of epilepsy and alcohol addiction with creatine |
| 01/23/2014 | WO2014014937A1 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation |
| 01/23/2014 | WO2014014933A1 Hiv treatment with amido-substituted pyrimidinone derivatives |
| 01/23/2014 | WO2014014901A1 Octahydro-cyclopentapyrrolyl antagonists of ccr2 |
| 01/23/2014 | WO2014014900A1 Histone deacetylase inhibitors and compositions and methods of use thereof |
| 01/23/2014 | WO2014014885A1 Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| 01/23/2014 | WO2014014874A1 Pyrazole derivatives which inhibit leukotriene production |
| 01/23/2014 | WO2014014845A1 Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| 01/23/2014 | WO2014014841A1 Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| 01/23/2014 | WO2014014828A1 Nicotinamide riboside to treat hearing loss |
| 01/23/2014 | WO2014014814A1 Compounds for the treatment and prevention of infections |
| 01/23/2014 | WO2014014794A2 Mineralocorticoid receptor antagonists |
| 01/23/2014 | WO2014014752A1 Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose |
| 01/23/2014 | WO2014014706A1 Nicotinamide derivate in the treatment of acute coronary syndrome |
| 01/23/2014 | WO2014014530A1 Ursolic acid salts for treating diabetes and obesity |
| 01/23/2014 | WO2014014519A1 Method of treating and preventing brain impairment using na+-k+ -2ci- cotransporter isoform 1 inhibitors |
| 01/23/2014 | WO2014014517A1 Method of ameliorating clotting pathologies and related materials and methods |
| 01/23/2014 | WO2014014515A2 Melanogenesis inhibition-methods and compositions thereof |
| 01/23/2014 | WO2014014434A1 Preparation for the treatment of tuberculosis |